MediWound (MDWD) Stock Forecast, Price & News

MediWound (NASDAQ:MDWD) Frequently Asked Questions

Is MediWound a buy right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MediWound in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MediWound stock.
View analyst ratings for MediWound or view top-rated stocks.

Are investors shorting MediWound?

MediWound saw a decline in short interest in the month of April. As of April 30th, there was short interest totaling 54,800 shares, a decline of 30.6% from the April 15th total of 79,000 shares. Based on an average daily volume of 116,100 shares, the days-to-cover ratio is presently 0.5 days. Currently, 0.3% of the shares of the company are short sold.
View MediWound's Short Interest.

When is MediWound's next earnings date?

MediWound is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022.
View our earnings forecast for MediWound.

How were MediWound's earnings last quarter?

MediWound Ltd. (NASDAQ:MDWD) issued its quarterly earnings results on Tuesday, May, 17th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. MediWound had a negative net margin of 57.03% and a negative trailing twelve-month return on equity of 3,540.43%. During the same period in the previous year, the firm earned ($0.10) EPS.
View MediWound's earnings history.

What price target have analysts set for MDWD?

4 brokerages have issued 1-year price targets for MediWound's shares. Their forecasts range from $6.50 to $8.00. On average, they expect MediWound's stock price to reach $7.13 in the next twelve months. This suggests a possible upside of 295.8% from the stock's current price.
View analysts' price targets for MediWound or view top-rated stocks among Wall Street analysts.

Who are MediWound's key executives?

MediWound's management team includes the following people:

• Mr. Sharon Malka CPA, MBA, Chief Exec. Officer (Age 50, Pay $497k)
• Prof. Lior Rosenberg M.D., Co-Founder & Chief Medical Technology Officer (Age 76, Pay $398k)
• Mr. Boaz Gur-Lavie CPA, M.B.A., Chief Financial Officer (Age 48, Pay $309k)
• Mr. Yaron Meyer Adv., Exec. VP, Gen. Counsel & Corp. Sec. (Age 43, Pay $240k)
• Dr. Ety Klinger, Chief R&D Officer (Age 60, Pay $344k)
• Mr. Stephen T. Wills CPA, CPA, MST, Exec. Chairman (Age 65)

Who are some of MediWound's key competitors?

Some companies that are related to MediWound include MariMed (MRMD), HEXO (HEXO), ChromaDex (CDXC), Grove (GRVI), IM Cannabis (IMCC), Natural Alternatives International (NAII), FitLife Brands (FTLF), Mannatech (MTEX), Bon Natural Life (BON), Charlie's (CHUCD), Charlie's (CHUC), Glucose Health (GLUC), Smart for Life (SMFL), Nutra Pharma (NPHC) and Happiness Development Group (HAPP).
View all of MDWD's competitors.

What other stocks do shareholders of MediWound own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MediWound investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), Blackstone (BX), Dynavax Technologies (DVAX), Geron (GERN), Idera Pharmaceuticals (IDRA), Mastercard (MA), SCYNEXIS (SCYX), Vascular Biogenics (VBLT) and Wells Fargo & Company (WFC).

What is MediWound's stock symbol?

MediWound trades on the NASDAQ under the ticker symbol "MDWD."

Who are MediWound's major shareholders?

MediWound's stock is owned by many different retail and institutional investors. Top institutional shareholders include Sargent Investment Group LLC (1.13%), Meitav Dash Investments Ltd. (0.93%), Acadian Asset Management LLC (0.08%), Warberg Asset Management LLC (0.07%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%).

Which institutional investors are selling MediWound stock?

MDWD stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, and Simplex Trading LLC.

Which institutional investors are buying MediWound stock?

MDWD stock was purchased by a variety of institutional investors in the last quarter, including Meitav Dash Investments Ltd., Warberg Asset Management LLC, and Sargent Investment Group LLC.

How do I buy shares of MediWound?

Shares of MDWD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is MediWound's stock price today?

One share of MDWD stock can currently be purchased for approximately $1.80.

How much money does MediWound make?

MediWound has a market capitalization of $59.54 million and generates $23.76 million in revenue each year. The biopharmaceutical company earns $-13.55 million in net income (profit) each year or ($0.51) on an earnings per share basis.

How many employees does MediWound have?

MediWound employs 77 workers across the globe.

What is MediWound's official website?

The official website for MediWound is www.mediwound.com.

How can I contact MediWound?

MediWound's mailing address is 42 HAYARKON STREET, YAVNE L3, 8122745. The biopharmaceutical company can be reached via phone at 972779714100, via email at [email protected], or via fax at 972-77-971-4111.